Acknowledgement
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), which is funded by the Ministry of Education, Science and Technology (2010005446), and by Korea Nazarene University Research Fund.
References
- Barsoumian HB, Batra L, Shrestha P, Bowen WS, Zhao H, Egilmez NK, Gomez-Gutierrez JG, Yolcu ES, Shirwan H. A novel form of 4-1BBL prevents cancer development via nonspecific activation of CD4(+) T and natural killer cells. Cancer Research. 2019. 79: 783-794. https://doi.org/10.1158/0008-5472.can-18-2401
- Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH. 4-1BBL enhances anti-tumor response in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cellular Immunology. 2001. 210: 56-65. https://doi.org/10.1006/cimm.2001.1804
- Habib-Agahi M, Jaberipour M, Searle PF. 4-1BBL costimulation retrieves CD28 expression in activated T cells. Cellular Immunology. 2009. 256: 39-46. https://doi.org/10.1016/j.cellimm.2009.01.003
- Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Research. 2009. 69: 8516-8525. https://doi.org/10.1158/0008-5472.CAN-09-2522
- Kim HS. Development of genetically modified tumor cell containing c0-stimulatory molecule. Biomedical Science Letters. 2019. 25: 398-406. https://doi.org/10.15616/BSL.2019.25.4.398
- Lee NK, Kim HS. Oncolytic vaccinia virus expressing 4-1BBL inhibits tumor growth by increasing CD8+ T cells in B16F10 tumor model. Biomedical Science Letters. 2012. 18: 210-217.
- Madireddi S, Schabowsky R-H, Srivastava AK, Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL costimulation inhibits conversion of conventiolnal CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ. PLoS One. 2012. 7: e42459. https://doi.org/10.1371/journal.pone.0042459
- Mock J, Stringhini M, Villa A, Weller M, Weiss T, Neri D. An engineered-4-1BBL fusion protein with "activity on demand". Proceedings of the National Academy of Sciences USA. 2020. 117: 31780-31788. https://doi.org/10.1073/pnas.2013615117
- Ragonnaud E, Andersson AM, Pedersen AE, Laursen H, Holst PJ. An adenoviral cancer vaccine co-endoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression. Vaccine. 2016. 34: 2147-2156. https://doi.org/10.1016/j.vaccine.2015.06.087
- Sharma RK, Yolcu ES, Shirwan H. SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccine. Expert Review of Vaccines. 2014. 13: 387-398. https://doi.org/10.1586/14760584.2014.880340
- Stephan MT, Ponomarev V, Brentjens RJ, Chang AH, Dobrenkov KV, Heller G, Sadelain M. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nature Medicine. 2007. 13: 1440-1449. https://doi.org/10.1038/nm1676
- Trub M, Uhlenbrock F, Claus C, Herzig P, Thelen M, Karanikas V, Bacac M, Amann M, Albrecht R, Ferrara-Koller C, Thommen D, Rothschield S, Savic Prince S, Mertz KD, Cathomas G, Rosenberg R, Heinzelmann-Schwarz V, Wiese M, Lardinosis D, Umana P, Klein C, Laubli H, Kashyap AS, Zippelius A. Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. Journal for Immunotherpy of Cancer. 2020. 8: e000238. https://doi.org/10.1136/jitc-2019-000238
- Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Molecular Cancer Therapeutics. 2012. 11: 1062-1070. https://doi.org/10.1158/1535-7163.MCT-11-0677
- Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunological Reviews. 2009. 229: 192-215. https://doi.org/10.1111/j.1600-065X.2009.00765.x
- Wang R, Freywald A, Chen Y, Xu J, Tan X, Xiang J. Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming CD44(+)CD62L(high)IL-7R(+) CTLs with up-and downregulation of anti- and pro-apoptosis genes. Cellular & Molecular Immnology. 2015. 12: 456-465. https://doi.org/10.1038/cmi.2014.72
- Yi KH, Nechushtan H, Bowers WJ, Walker GR, Zhang Y, Pham DG, Podack ER, Federoff HJ, Yolba KA, Rosenblatt JD. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo. Cancer Research. 2007. 67: 10027-10037. https://doi.org/10.1158/0008-5472.CAN-06-2391